TY  - JOUR
AU  - Liu, Kang
AU  - Yang, Lin
AU  - Zhang, Xiao-Ming
AU  - Zhou, Yi
AU  - Zhu, Tao
AU  - Miao, Nan-Dong
AU  - Ren, Yong-Jun
AU  - Xu, Hao
AU  - Min, Xu-Li
AU  - Peng, Juan
AU  - Yang, Ke
AU  - Yang, Shi
PY  - 2017
TI  - HIF-1α and VEGF levels for monitoring hepatocellular carcinoma treatment response to transcatheter arterial chemoembolization
JF  - Translational Cancer Research; Vol 6, No 6 (December 28, 2017): Translational Cancer Research
Y2  - 2017
KW  - 
N2  - Background: The purpose of the present study was to investigate the use of hypoxia-inducible factor-1 alpha (HIF-1α) and vascular endothelial growth factor (VEGF) levels to monitor the treatment response to transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC).   Methods: A total of 41 consecutive HCC patients underwent TACE were enrolled into this study. The serum levels of HIF-1α and VEGF were measured using enzyme-linked immunosorbent assays (ELISAs) 1 day before, and 1, 7 and 28 days after TACE therapy. The overall tumor response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors criteria. Patients with a complete response or partial response comprised the responding group, whereas those with stable disease or progressive disease comprised the non-responding group. The differences in serum HIF-1α and VEGF levels before and after TACE therapy were subjected to analysis of nonparametric test, while correlations between serum HIF-1α and VEGF levels were examined using Pearson’s correlation analysis. Receiver-operating characteristic (ROC) curve was applied to analyze the evaluation value of factors for the response of TACE on the treatment of HCC. P
UR  - https://tcr.amegroups.org/article/view/16097